PYGL抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: PC3 cells, human fetal liver tissue, Primary antibody: P08657(PYGL Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08657(PYGL Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08657(PYGL Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

PYGL antibody targets the PYGL gene-encoded protein, glycogen phosphorylase liver-type, a key enzyme in glycogenolysis. PYGL catalyzes the cleavage of glycogen into glucose-1-phosphate, a critical step in maintaining blood glucose levels during fasting. Primarily expressed in the liver, PYGL activity is tightly regulated by allosteric effectors and phosphorylation, with hormonal signals (e.g., glucagon) activating it via cAMP-dependent pathways. Dysregulation of PYGL is linked to metabolic disorders, including glycogen storage disease type VI (Hers disease), characterized by hepatomegaly and hypoglycemia.

PYGL antibodies are essential tools in research, enabling the detection and quantification of PYGL protein in tissues or cell lysates using techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies aid in studying hepatic glucose metabolism, pathological mechanisms of glycogen-related diseases, and potential therapeutic targets. Additionally, they help investigate PYGL's role in hepatocellular carcinoma, where altered glycogen metabolism is observed. Commercial PYGL antibodies are typically raised in rabbits or mice, validated for specificity to avoid cross-reactivity with muscle (PYGM) or brain (PYGB) isoforms. Their application extends to preclinical models, enhancing understanding of metabolic adaptation and liver function.